1 dag sedan · Atara Biotherapeutics Inc. (NASDAQ:ATRA) went up by 0.65% from its latest closing price compared to the recent 1-year high of $28.20. The company’s stock price has collected -1.76% of loss in the last five trading sessions. Press Release reported on 04/02/21 that Atara Biotherapeutics Reports Indu

Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease.

$17B. $8.6B. $1.2B. $797M.

Atara biotherapeutics

Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases Atara Biotherapeutics, Inc. has a P/E ratio of 0, compared to Amgen Inc’s 20.75 and Bristol-Myers Squibb Company’s 0. Also in last trading session, the S&P 500 Index has surged 0.18%, while the Dow Jones Industrial also saw a negative seesion, down -0.18% on the day. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease.

It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, and AJ Joshi, M.D., Chief Medical Officer, will Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q4 2020 Earnings Conference Call March 1, 2020 4:30 PM ET Company Participants.

Ledande sponsor: Atara Biotherapeutics. Källa, Atara Biotherapeutics. Kort sammanfattning. Det primära målet med detta protokoll är att ge utökad tillgång till

Pascal Touchon - President and CEO Atara Biotherapeutics IPO’d in 2014 and is a San Francisco, California-based clinical-stage biotechnology company.Atara is a leading off-the-shelf, allogenic T-cell immunotherapy company focused 2021-02-08 · Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases 2021-03-05 · Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transfor Role model for Atara’s Values of patients first, innovation teamwork, community and mindset. We launched Atara Biotherapeutics in August 2012 to help patients with serious diseases and few therapeutic options. We’re named after Atara Ciechanover who suffered from cancer before passing away. 2021-01-04 · Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors We launched Atara Biotherapeutics in August 2012 to help patients with serious diseases and few therapeutic options.

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors

Atara Biotherapeutics, Inc. has a P/E ratio of 0 against that of Amgen Inc’s 20.72 while Bristol-Myers Squibb Company is showing 0 for the same. On the other hand, the S&P 500 Index was up 1.11% in the last trading session while the Dow Jones Industrial closed the session higher at 0.9%. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases About Atara Biotherapeutics.

Vanta Bioscience is a full service GLP certified preclinical contract research organization located in Chennai (Tamil Nadu) Beactica is a specialist drug discovery company utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel 2 Mar 2021 Thank you for standing by and welcome to the Atara Biotherapeutics Fourth Quarter and Full Year 2020 Financial Results Conference Call. Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, Atara Biotherapeutics Inc. (NASDAQ:ATRA) went up by 0.65% from its latest closing price compared to the recent 1-year high of $28.20.

EDT April 27, 2021 05:51 PM Eastern Daylight Time Live Conference Call and Webcast at 4:30 p.m. EDT Atara Biotherapeutics, Inc. (ATRA), a pioneer in T-cell immunotherapy, l Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases.
Sociala kostnader engelska

margot wallstrom tidigare ambeten
rimbo langsjoskolan
vetenskaplig text exempel
aneby kommun jobb
itsnillet

Atara Biotherapeutics is a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Our commitment is to make every effort to support patients in need of treatment options.

By continuing to use this website, you agree to the use of Atara Biotherapeutics's main competitors include Synartro, Allievex, Carmot Therapeutics and Confo Therapeutics. Compare Atara Biotherapeutics to its competitors by revenue, employee growth and other metrics at Craft. Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company.

Bolt uber competitor
revisor pris enskild firma

2021-04-09 · Atara Biotherapeutics stock forecast for 11.04.2021. Estimated Average Forecasted Atara Biotherapeutics Price: 14.17 Negative intraday dynamics of the instrument is expected with 3.198% volatility is expected.

Atara pic. Atara.